Lexeo Therapeutics Statistics
Total Valuation
LXEO has a market cap or net worth of $87.31 million. The enterprise value is -$3.12 million.
Important Dates
The last earnings date was Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LXEO has 33.20 million shares outstanding. The number of shares has increased by 176.82% in one year.
| Current Share Class | 33.19M |
| Shares Outstanding | 33.20M |
| Shares Change (YoY) | +176.82% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 4.52% |
| Owned by Institutions (%) | 77.96% |
| Float | 19.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.99 |
| P/TBV Ratio | 0.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.42, with a Debt / Equity ratio of 0.11.
| Current Ratio | 3.42 |
| Quick Ratio | 3.24 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -908.44 |
Financial Efficiency
Return on equity (ROE) is -80.65% and return on invested capital (ROIC) is -49.83%.
| Return on Equity (ROE) | -80.65% |
| Return on Assets (ROA) | -42.89% |
| Return on Invested Capital (ROIC) | -49.83% |
| Return on Capital Employed (ROCE) | -122.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.52M |
| Employee Count | 72 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.98% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -79.98% |
| 50-Day Moving Average | 3.07 |
| 200-Day Moving Average | 6.91 |
| Relative Strength Index (RSI) | 41.34 |
| Average Volume (20 Days) | 915,472 |
Short Selling Information
The latest short interest is 3.26 million, so 9.83% of the outstanding shares have been sold short.
| Short Interest | 3.26M |
| Short Previous Month | 2.94M |
| Short % of Shares Out | 9.83% |
| Short % of Float | 16.44% |
| Short Ratio (days to cover) | 2.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | -74.09M |
| Operating Income | -116.28M |
| Pretax Income | -69.42M |
| Net Income | -109.31M |
| EBITDA | -115.67M |
| EBIT | -116.28M |
| Earnings Per Share (EPS) | -$3.31 |
Full Income StatementBalance Sheet
The company has $99.83 million in cash and $9.40 million in debt, giving a net cash position of $90.43 million or $2.72 per share.
| Cash & Cash Equivalents | 99.83M |
| Total Debt | 9.40M |
| Net Cash | 90.43M |
| Net Cash Per Share | $2.72 |
| Equity (Book Value) | 88.12M |
| Book Value Per Share | 2.65 |
| Working Capital | 74.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$88.00 million and capital expenditures -$296,000, giving a free cash flow of -$88.30 million.
| Operating Cash Flow | -88.00M |
| Capital Expenditures | -296,000 |
| Free Cash Flow | -88.30M |
| FCF Per Share | -$2.66 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |